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Introduction: Adherence, which is crucial to the success of antiretroviral therapy (HAART), is
currently a major challenge in the care of children and adolescents living with HIV/AIDS.
Objective: To evaluate the prevalence of nonadherence to HAART using complementary
instruments in a cohort of children and adolescents with HIV/AIDS followed in a reference
service in Campinas, Brazil.
Methods: The level of adherence of 108 patients and caregivers was evaluated by an adapted
standardized questionnaire and pharmacy dispensing records (PDR). Non-adherence was
deﬁned as a drug intake lower than 95% (on 24-hour or seven-day questionnaires), or as
an interval of 38 days or more for pharmacy reﬁlls. The association between adherence
and clinical, immunological, virological, and psychosocial characteristics was assessed by
multivariate analysis.
Results: Non-adherence prevalence varied from 11.1% (non-adherent in three instruments),
15.8% (24-hour self-report), 27.8% (seven-day self-report), 45.4% (PDR), and 56.3% (at least
one of the outcomes). 24-hour and seven-day self-reports, when compared to PDR, showed
low sensitivity (29% and 43%, respectively) but high speciﬁcity (95% and 85%, respectively).
In multivariate analysis, medication intolerance, difﬁculty of administration by caregiver,
HAART intake by the patient, lower socioeconomical class, lack of virological control,missed
appointments in the past six months, and lack of religious practice by caregiver were sig-
niﬁcantly associated with non-adherence.evaleConclusion: A high prtion, and PDR was the mo
were complementary in th
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Introduction
Upon the beginning of the fourth decade of the acquired
immunodeﬁciency syndrome (AIDS) pandemic, the propor-
tion of children and families affected by human immunodeﬁ-
ciency virus (HIV) infection remains an increasingly important
global public health problem. It is estimated that there are
more than 33 million people living with the disease across
the world.1 In Brazil every year, around 35,000 new cases are
reported, with an estimate of 635,000 people (0.33% of the gen-
eral population) living with HIV.2 Since the beginning of the
epidemic, around 18,000 AIDS cases were reported in Brazil-
ian children younger than 13 years old, approximately 95% of
which were vertically acquired. Around 16,600 children born
to HIV-infected mothers were yearly reported, and 815 new
pediatric caseswere reported in 2010 alone, for a vertical trans-
mission rate of 4.9%. Such a rate is higher than the targeted
goal, since a national protocol for prevention of vertical trans-
mission began to be implemented in 1999.3,4
The introduction of highly active antiretroviral therapy
(HAART) led to a signiﬁcant reduction in mortality and
increase in the quality of life of people affected by the
disease.4,5 According to data from the World Health Orga-
nization, more than ﬁve million people are now receiving
treatment, but this is estimated to be only 35% of people who
need therapy.6 In Brazil, as a part of a public health policy coor-
dinated by the Department of Sexually Transmitted Diseases,
AIDS, and Viral Hepatitis of the Ministry of Health, access to
antiretroviral therapy is universal and free of charge, currently
beneﬁting around 200,000 patients.7
In the current scenario, a major challenge faced by health
services is to ensure proper adherence to therapy, indispens-
able for adequate control of the disease. Studies show that
children and adolescents comprise a group with increased
vulnerability in adherence to treatment, who require effec-
tive monitoring to maintain the sustainability of a lifelong
therapy.8,9 Inappropriate adherence to antiretroviral therapy
causes serious consequences to people living with HIV/AIDS,
with increased risk of viral resistance, immune deterioration,
opportunistic infections anddeath, since the aims of the treat-
ment are the control of virus replication, and preservation or
recovery of immunocompetence.10,11
Several studies analyzing the factors associated with non-
adherence, using different assessment methods, individually
or in association, are found in the literature. In most of the
reports adherence of patients or caregivers was ascertained by
means of response to questionnaires, either by self-report or
by interviews led by health professionals.12–16 Other resources
include data from pharmacy dispensing records (PDR);17,18
electronic drug monitoring (EDM);19–21 subjective assess-
ment by health professionals;22 counting of pills returned
by patients, in the patient’s home or by telephone;23,24 and
serum drug level determination.25 Overall, the results from
the above studies demonstrate a high degree of heterogeneity
in adherence outcomes, suggesting the potential usefulness
of complementary approaches.The objective of this study was to assess adherence to
HAART and the factors associated with non-adherence, using
complementary methods, in a population of HIV-infected12;16(4):315–320
Brazilian children and adolescents attending a reference cen-
ter.
Materials and methods
An observational, cross-sectional study was performed at the
Pediatric Immunodeﬁciency Clinic at theHospital da Universi-
dade Estadual de Campinas, which is responsible for the care
of HIV-infected children and adolescents from the metropoli-
tan area of the city of Campinas, state of São Paulo, Brazil. All
129 children and adolescents followed at this reference center,
aged 7 to 19 years-old, were initially selected to participate in
the study. Patientswithmental retardation, implying cognitive
impairment and neurological diseases, which hindered the
understanding of the issues proposed, were excluded. A total
of 108 patients (60 males) were evaluated during the period
from November, 2008, to December, 2009.
Adherence was assessed using an adapted standardized
questionnaire,26 and by PDR for antiretrovirals, using data
from the Logistic Antiretroviral Medicines Control System
(Sistema de Controle Logístico de Medicamentos–SICLOM),
a centralized pharmacy dispensing system with nationwide
coverage. Interviewed patients and/or their caregivers were
asked about the administration of prescribed medication in
the last 24hours and also in the last seven days. The ques-
tionnaire format provided a result in terms of percent of
adherence, from 0% to 100%. Patients were considered non-
adherent if, in response to the questionnaire, they reported
receiving less than 95% of prescribed doses in the previous
24hours or seven days. The cutoff value of 95% was chosen
due to its association with the effective control of viral repli-
cation andprevention of resistance toHAART.27 In the analysis
of SICLOM records, patients were considered non-adherent
if an interval of 38 days or more had elapsed from the last
reﬁll of antiretrovirals, according to recommendations issued
by the Brazilian Ministry of Health.28 Due to the characteris-
tic of the SICLOM records, which are independent both from
the patient’s report and the examiner’s records, PDR data were
used as standards for the evaluation of the accuracy of 24-hour
and seven-day questionnaire data. Sensitivity, speciﬁcity, and
positive and negative predictive values were thus calculated
for 24-hour and seven-day questionnaire outcomes.
Data were also collected on the following independent
variables, related to demographical, social, clinical, immuno-
logical and virological conditions: gender, age, socioeconomic
status,29 patient and caregiver schooling, caregiver employ-
ment status, family income, knowledge of the diagnosis by
the patient, HIV caregiver status, HAART use by caregiver,
illicit drug use by caregiver, quality of life scores (using
the PedsQL 4.0TM inventory),30 orphaned state of patient,
adoptive caregivers, missed clinic appointments, religious
practice by patient or caregiver, difﬁculties in the admin-
istration of medicines, person in charge for administering
medicines, medication intolerance, clinical and immunolog-
ical classiﬁcation,31 HAART complexity, number of previous
antiretroviral regimens, protease inhibitor usage, recent HIV
viral load and lymphocyte subpopulation counts, and HIV
resistance.
All interviews were conducted by the ﬁrst author of the
study, in a designated room, for approximately 30minutes.
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Table 1 – Clinical and demographic characteristics of 108
study subjects.
Variable Values
Male gender* 60 (55.5%)
Age in years† 13.22 (7.9–19.6)
Socioeconomic level*
A+B 25 (23.1%)
C+D 83 (76.9%)
Caregiver education level*
High School or higher 30 (27.8%)
Elementary School or lower 78 (72.2%)
Patient education level*
High School or higher 24 (22.2%)
Elementary School or lower 84 (77.8%)
Monthly per capita income (US dollars)† 185.18 (11.1–1.296.27)
Knowledge of diagnosis by patient* 65 (60.2%)
HIV-infected primary caregiver* 57 (52.8%)
Use of HAART by caregiver* 52 (48.1%)
Employed caregiver* 52 (48.1%)
Illicit drug use by the caregiver* 1 (0.9%)
PedsQL 4.0 score - caregiver† 85.8 (9.78–98.9)
PedsQL 4.0 score - patient† 84.7 (34.7–100)
Orphanhood in relation to at least one
biological parent*
61 (56.5%)
Foster or institutional caregiver* 44 (40.7%)
One or more missed appointments in the last
6 months*
32 (29.6%)
Practice of religion by the caregiver 60 (55.6%)
Practice of religion by the patient* 59 (54.6%)
Difﬁculty in drug administration by caregiver* 19 (17.6%)
HAART administered by caregiver* 76 (70.4%)
CDC clinical classiﬁcation*
N, A or B 77 (71.3%)
C 31 (28.7%)
Therapeutic regimen*
Low complexity (less than 4 ARVs) 72 (66.7%)
High complexity (4 or more ARVs) 36 (33.3%)
Number of prior ART regimens*
Four or more 59 (54.6%)
Less than 4 49 (45.4%)
Use of a protease inhibitor* 66 (61.1%)
Intolerance to medication* 19 (17.6%)
CD4+ lymphocyte count<500/mm3* 24 (22.2%)
CD4/CD8 ratio≥ 1* 22 (20.4%)
Controlled viral replication (< 50 copies/mL)* 54(50%)
Resistance to ARVs (34 subjects)†
Classes 3 (0–4)
NRTI 5(0–6)
NNRTI 2(0–2)
PI 3(0–8)
Total ARV 10(0–16)
*proportions; †median and extreme; CDC, Centers for Disease
Control and Prevention/Ministry of Health; HAART, highly active
antiretroviral therapy; NRTI, reverse transcriptase inhibitors,braz j infect d i s .
All patients and/or caregivers were informed of the details
f the study, and those, or their legal representatives, who
greed to participate were asked to sign an informed consent.
he study was approved by the local Committee of Ethics in
esearch (statement 711/2008).
Study data were stored and analyzed with the Statistical
ackage for the Social Sciences (SPSS) for Windows, version
6.0 (SPSS Inc., Chicago–IL, USA). Riskwas assessed by calcula-
ion of odds ratios (OR) and 95% conﬁdence intervals. Raw OR
alues were determined by univariate logistic regression, by
he “Enter”method. AdjustedOR and 95% conﬁdence intervals
ere obtained by multivariate logistic regression, “forward
ald” method, with inclusion p-values of 0.05 and exclusion
-values of 0.10.
esults
total of 108 patient-caregiver dyads were interviewed. The
ain clinical and demographic characteristics of the study
opulation are shown in Table 1.
The prevalence of non-adherence varied from 15.8% (24-
our questionnaire), and 27.8% (seven-day questionnaire)
o 45.4%, according to PDR. A total of 11.1% of patients
ere considered non-adherent in all three instruments, and
4.6% were considered non-adherent in at least one of them.
tatistically signiﬁcant non-adherence risk factors for com-
lementary instruments after multivariate analysis were:
ifﬁculty of medicine administration by the caregiver, del-
gation of responsibility of medicine administration to the
hild or adolescent patient, lower socioeconomic class, lack
f virological control, lack of religious practice by the care-
iver,missed clinic appointments, andmedication intolerance
Table 2).
In relation to PDR, data from 24-hour and seven-day ques-
ionnaires showed low sensitivity, but good speciﬁcity and
ositive predictive values (Table 3).
iscussion
n the population studied, the evaluation of PDR proved to be
n instrument capable of detecting a higher prevalence of fail-
re to adhere to ART (45.4%), when compared to standardized
uestionnaires (15.8% for 24-hour recall and 27.8% for seven-
ay recall). The lowest prevalence of non-adherence was
bserved when considering the three simultaneous instru-
ents (11.1%), and the highest prevalence (56.3%) when
ndividuals were considered non-adherent by at least one of
he instruments. To the authors’ knowledge, this is the ﬁrst
tudy to make such comparison in Latin America. Several
ediatric studies have shown, similarly, the usefulness of PDR
nalysis as an indicator of adherence with ART, highlighting
ts direct association with control of viral replication, in both
eveloped and developing countries.15,20,32–34
The usefulness of PDR analysis was also emphasized by
rossberg et al.17 in a study with adults in the U.S., which
bserved a higher sensitivity and better association with the
irologic response of PDR, when compared to self-report.
isson et al.,35 and Rougemont et al.,36 also with adults,
bserved PDR to be more sensitive than the CD4+nucleoside analog; NNRTI, reverse transcriptase inhibitors, non-
nucleoside; IP, protease inhibitor.
T-lymphocyte count as a predictor of virologic failure. In
contrast, Acri et al.,21 reported low correlation between EDM
and PDR in a study in adults. However, the authors pointed out
that the PDR data in that report were obtained retrospectively
318 braz j infect d i s . 2012;16(4):315–320
Table 2 – Comparison of complementary adherence outcomes after multivariate analysis.
Independent variable 24-hour questionnaire 7-day questionnaire Pharmacy dispensing
records
Odds Ratio 95% CI Odds Ratio 95% CI Odds Ratio 95% CI
Intolerance to medication 9.11 2.87–28.98
Difﬁculty in administering medication 2.91 1.05–8.12
Medicine administration by patient 3.59 1.47–8.78
Lower socioeconomic class 3.54 0.97–2.85
Lack of virological control (≥50 copies/mL) 3.73 1.68–8.31
Caregiver without religious practice 3.19 1.36–7.50
One or more missed appointments in the
last 6 months
Table 3 – Parameters of comparison between 24-hour
and seven-day questionnaires, using pharmacy
dispensing records as standards.
24-hour
questionnaire
7-day
questionnaire
Positive predictive value 82% 70%
Negative predictive value 38% 64%
Sensitivity 29% 43%
Speciﬁcity 95% 85%
about caregivers was found in the literature, but it is possible
that religious practice provides stronger community support,from commercial pharmacies, rather than from a centralized
PDR, which was the case in the present study.
In a recent review, Bangsberg37 highlighted the practi-
cality of using PDR, with the advantage of not relying on
expensive devices, and also, in relation to self-report, of its
independence from patient cooperation. The characteristics
of such pharmacy registry in the health services of hospitals
of the present study, with universal distribution of antiretro-
virals and centralized dispensation with physical proximity
to the outpatient service, plus the 30-day provision limits
and computerized control, make this quite simple procedure
a practical and feasible instrument for adherence control.
Due to these characteristics, PDR monitoring has been rec-
ommended by the Ministry of Health.31
The 45.4% non-adherence rate detected in the present
study by PDR appears to be higher than usually reported.
Systematic reviews of international pediatric studies related
variability in the prevalence of adherence between 49%
and 100%, with 76% of studies reporting adherence above
75%, with a trend towards greater adherence in developing
countries.32,34 These contrasting results are probably mainly
due to the usually higher sensitivity of PDR,when compared to
the most commonly used self-report or interview methods.37
In order to identify not only the prevalence of adherence
failure, but also the associated risk factors, providing a foun-
dation for successful interventions, there is a tendency in the
literature to recommend the combination of methods, as used
in this study. The results of several studies with different sce-
narios reinforce these recommendations.23,38 Noteworthy are
the data obtained by Llabre et al.39 that, in a longitudinal study,
used different methods for measuring adherence (self-report,
interviews and EDM), on multiple occasions. Consistently, the
use of at least two methods was signiﬁcantly associated with
control of viral replication.3.27 1.38–7.78
Among the independent variables analyzed in the present
study, multivariate analysis found seven risk factors for
non-adherence: difﬁculty of medicine administration by the
caregiver, delegation of responsibility of medicine adminis-
tration to the child or adolescent patient, lower socioeconomic
class, lackof virological control, lackof religiouspractice by the
caregiver, missed clinic appointments, and medication intol-
erance.
The difﬁculty of administration ofmedicationwas reported
as a non-adherence risk factor, associated with higher viral
loads, by Allison et al.,40 in a study with caregiver interviews.
In contrast with the present study, Biadgilign et al.41 reported
that 97.4% of participants had positive attitudes regarding the
administration of antiretroviral drugs, despite 22.3% reporting
particular difﬁculties, such as children spitting the medica-
tion, resistance and refusal, and the need for simultaneous
administration of several drugs.
Although this analysis reveals the delegation of responsi-
bility of administration of ART to pediatric patients as a risk
factor for adherence failure, no other reports in the litera-
ture that have directly addressed this important association
were found. An analogous situation, however, is reported by
Williams et al.,42 who identiﬁed improved adherence in situ-
ations of care provided by caregivers without a biological con-
nection, or in cases of social support systems aimed at helping
adolescents to remember the timing of medication doses. In
the authors’ interpretation, delegating to adolescents their
own care in situations of chronic disease, without close super-
vision, may constitute an excessive responsibility burden.
An association between lower socioeconomic class and risk
of non-adherence was observed. Similar ﬁndings were also
reported by Cupsa et al.,43 in a pediatric adherence study in
Romania. In the authors’ view, lower family income may act as
a social stress feature, with potential harmful consequences
to a succesful therapy.
The group of patients whose caregivers reported regu-
lar religious practice showed a signiﬁcantly lower prevalence
of non-adherence. These results are consistent with those
observed by Park and Nachman,44 who analyzed the pat-
terns of adherence to ART in relation to religious beliefs in
anadolescentHIV-infectedpopulation. Individualswith excel-
lent adherence had signiﬁcantly higher scores of religious
beliefs than those who had low adherence. No speciﬁc datawhich may be helpful in the setting of a chronic disease.
201
f
i
t
c
t
w
i
s
t
a
t
r
e
t
u
m
s
d
t
w
d
n
q
a
c
p
i
p
a
T
c
h
h
c
e
C
I
u
w
u
a
f
h
a
w
s
o
p
a
o
w
r
r
1
1braz j infect d i s .
The association of missed appointments with adherence
ailure is straightforward. Absentees are at greater risk of fail-
ng to follow the treatment properly. Vreeman et al.32 reported
hatmore than half of the children have lost at least amonthly
onsultation, but these authors did not approach the associa-
ion with treatment adherence.
Intolerance to antiretrovirals was signiﬁcantly associated
ith lower adherence, according to the evaluation measures
n the 24hours preceding the interview. A qualitative analy-
is in order to obtain a deeper understanding of the factors
hat inﬂuence adherence to antiretroviral therapy in a pedi-
tric population in Southern India described factors related
o the drugs that inﬂuence adherence, showing comparable
esults. The difﬁculty of adherence was associated with side
ffects, size and arrangements of the tablets, and ﬂavor and
aste of pediatric formulations.45
Viral load, as a frequent clinical analysis procedure, of
tmost importance in its relationship to a successful treat-
ent, appears as an important adherence factor in most
tudies related toART. The present study revealed a signiﬁcant
irect association between virological control and adherence
o treatment, as measured by pharmacy data. Similar results
ere presented by several other reports.15,17,20,24,25,33,40,42
The main limitation of this study is its cross-sectional
esign, causing susceptibility to confounding factors. Also,
one of the adherence instruments used is ﬂawless. Theuse of
uestionnaires in interviews involves subjective factors such
s memory difﬁculties and embarrassment of the patient or
aregiver, whomay fear the judgment on the part of the health
rofessional.46 PDR, which is considered to be a preferred
nstrument, is also susceptible to errors. It is not possible to
rove whether the dispensed drug was effectively ingested,
t the right schedule, and that it reached therapeutic levels.
here is a risk of overestimating adherence failures, espe-
ially in short-term approaches in the case of patients who
ave small stocks of medicines at home. The authors believe,
owever, that most of these deﬁciencies are overcome in this
ountry, by the centralization of dispensing and the comput-
rized control of reﬁlls.
onclusions
n the population studied there was a high prevalence of fail-
re of adherence to ART, with higher detection sensitivity
hen using pharmacy dispensation records. The instruments
sed were complementary in identifying risk factors for non-
dherence.
Adherence failure can result in catastrophic consequences
or the patient and the community, potentially resulting in
igher morbidity and even death. In a scenario of universal
ccess to treatment, as in Brazil, a public health initiative
hose merit is internationally recognized, such an outcome
hould not be accepted. These facts highlight the importance
f encouraging health services to adopt a proactive stance to
revent uncontrolled viral replication, assuring better survival
nd quality of life for patients who need a lifelong course
f therapy. To achieve this goal, the risk factors associated
ith non-adherence, as identiﬁed in this study, should be
outinely considered during the follow-up of patients and
12;16(4):315–320 319
their caregivers in order to plan speciﬁc interventions. Due
to its sensitivity and feasibility, adherence assessment by PDR
should be included in the routine preparation of patient visits.
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